Key Points
- Insider sale: Director Elizabeth Anderson sold 5,000 shares on November 24 at an average price of $204.58 for about $1.02 million, trimming her stake by 7.85% to 58,729 shares.
- In the quarter ended Oct. 30 Insmed reported EPS of ($1.75), missing estimates by $0.40, while revenue of $142.3 million beat expectations and rose 52.4% year-over-year, though the company still shows negative margins and return on equity.
- Analysts maintain a consensus rating of Moderate Buy with an average price target of $175.53, even as several firms have raised targets (e.g., TD Cowen $231, RBC $215), signaling generally constructive but varied views.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) Director Elizabeth Anderson sold 5,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $204.58, for a total value of $1,022,900.00. Following the sale, the director directly owned 58,729 shares in the company, valued at approximately $12,014,778.82. The trade was a 7.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Insmed Trading Down 2.2%
Shares of INSM stock opened at $204.51 on Thursday. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $209.77. The company has a market capitalization of $43.62 billion, a price-to-earnings ratio of -35.82 and a beta of 1.05. The firm has a 50-day moving average price of $171.50 and a 200 day moving average price of $128.13. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.
Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The firm had revenue of $142.34 million for the quarter, compared to analysts' expectations of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business's quarterly revenue was up 52.4% on a year-over-year basis. During the same period in the previous year, the company posted ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. Research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Insmed
Hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC grew its position in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 53 shares in the last quarter. Kingsview Wealth Management LLC lifted its position in shares of Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company's stock worth $334,000 after purchasing an additional 60 shares in the last quarter. Choreo LLC boosted its stake in shares of Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company's stock valued at $334,000 after purchasing an additional 65 shares during the period. Spire Wealth Management grew its holdings in Insmed by 11.5% during the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company's stock valued at $112,000 after purchasing an additional 80 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 81 shares in the last quarter.
Analysts Set New Price Targets
A number of brokerages have issued reports on INSM. Mizuho set a $196.00 price target on Insmed in a research note on Wednesday, October 29th. Morgan Stanley raised their target price on shares of Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Evercore ISI reaffirmed an "outperform" rating and set a $180.00 price target on shares of Insmed in a research report on Wednesday, October 1st. TD Cowen lifted their price target on shares of Insmed from $223.00 to $231.00 and gave the company a "buy" rating in a report on Thursday, November 20th. Finally, Royal Bank Of Canada boosted their price objective on shares of Insmed from $139.00 to $215.00 and gave the company an "outperform" rating in a research note on Friday, October 31st. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $175.53.
View Our Latest Analysis on INSM
About Insmed
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
